These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 8786626)
21. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group. Spencer RC Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900 [TBL] [Abstract][Full Text] [Related]
22. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1992). I. Susceptibility distribution]. Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H Jpn J Antibiot; 1995 Nov; 48(11):1627-57. PubMed ID: 8558754 [TBL] [Abstract][Full Text] [Related]
23. In vitro antibacterial activity of men 10700, a new penem antibiotic. Varotto F; Parravidini E; De Luca M; Casini A; Fraschini F Chemotherapy; 1999; 45(6):405-10. PubMed ID: 10567770 [TBL] [Abstract][Full Text] [Related]
24. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). I. Susceptibility distribution]. Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H Jpn J Antibiot; 1995 Nov; 48(11):1757-87. PubMed ID: 8558757 [TBL] [Abstract][Full Text] [Related]
25. [Preclinical evaluation of meropenem, a new parenteral carbapenem]. Edwards JR New Microbiol; 1995 Oct; 18 Suppl():19S-31S. PubMed ID: 8574929 [TBL] [Abstract][Full Text] [Related]
26. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1991). I. Susceptibility distribution]. Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H Jpn J Antibiot; 1995 Oct; 48(10):1394-421. PubMed ID: 8544337 [TBL] [Abstract][Full Text] [Related]
27. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution]. Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177 [TBL] [Abstract][Full Text] [Related]
28. In vitro activity of HRE 664, a penem antibiotic. Chin XN; Neu HC Diagn Microbiol Infect Dis; 1990; 13(6):509-16. PubMed ID: 2279381 [TBL] [Abstract][Full Text] [Related]
29. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Jones RN; Sader HS; Fritsche TR; Pottumarthy S Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923 [TBL] [Abstract][Full Text] [Related]
30. Antibacterial effect of imipenem in vitro against important aerobic and anaerobic strains isolated from clinical specimens. Klietmann W; Focht J; Nösner K Chemioterapia; 1987 Aug; 6(4):243-50. PubMed ID: 3477332 [TBL] [Abstract][Full Text] [Related]
31. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group. Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641 [TBL] [Abstract][Full Text] [Related]
32. [Antibacterial activity of biapenem against recent clinical isolates]. Hara T; Araake M; Watabe H Jpn J Antibiot; 2003 Apr; 56(2):138-41. PubMed ID: 12825414 [TBL] [Abstract][Full Text] [Related]
33. The in-vivo antibacterial activity of ceftazidime (Gr 20263)--a comparison with other new beta-lactam antibiotics and gentamicin. Acred P; Ryan DM; Sowa MA; Watts CM J Antimicrob Chemother; 1981 Sep; 8 Suppl B():247-55. PubMed ID: 19802994 [TBL] [Abstract][Full Text] [Related]
34. [Susceptibilities of clinical bacterial isolates to antimicrobial agents. A study mainly focused on imipenem. Reported by the Research Group for Testing Imipenem Susceptibility on Clinical Isolates]. Igari J Jpn J Antibiot; 1990 Nov; 43(11):1956-2002. PubMed ID: 2287060 [TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. Koga T; Abe T; Inoue H; Takenouchi T; Kitayama A; Yoshida T; Masuda N; Sugihara C; Kakuta M; Nakagawa M; Shibayama T; Matsushita Y; Hirota T; Ohya S; Utsui Y; Fukuoka T; Kuwahara S Antimicrob Agents Chemother; 2005 Aug; 49(8):3239-50. PubMed ID: 16048932 [TBL] [Abstract][Full Text] [Related]
36. [In-vitro activity of panipenem against clinical isolates in 2006]. Yoshida S; Koga T; Kakuta M; Kobayashi I; Matsuzaki K; Urabe E; Omika K; Hasegawa M; Sato Y Jpn J Antibiot; 2008 Feb; 61(1):1-17. PubMed ID: 18536215 [TBL] [Abstract][Full Text] [Related]
37. In vitro antibacterial activity and beta-lactamase stability of SY5555, a new oral penem antibiotic. Inoue E; Mitsuhashi S Antimicrob Agents Chemother; 1994 Sep; 38(9):1974-9. PubMed ID: 7811005 [TBL] [Abstract][Full Text] [Related]
39. In vitro antibacterial activities of FK037: a new parenteral cephalosporin. Inoue K; Inoue E; Mitsuhashi S Chemotherapy; 1995; 41(4):257-66. PubMed ID: 7555206 [TBL] [Abstract][Full Text] [Related]
40. [Susceptibilities of clinical bacterial isolates to antimicrobial agents. A study mainly focused on imipenem. Research Group for Testing Imipenem Susceptibility on Clinical Isolates]. Igari J Jpn J Antibiot; 1990 Oct; 43(10):1723-82. PubMed ID: 2086814 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]